The article discusses the urgent need for new drugs to treat schistosomiasis, a disease caused by flatworms that affects over 200 million people. The current drug of choice, praziquantel, has shown limited efficacy and there is evidence of drug-resistant parasites. Thioredoxin glutathione reductase (TGR) has been identified as a potential new target for drug development. The authors have developed a 1536-well-based kinetic HTS assay to screen potential TGR inhibitors, using furoxan as a positive control. The assay involves measuring the reduction of 5, 5'-dithiobis (2-nitrobenzoic acid) (DTNB) by NADPH and the increase in absorbance at 412 nm of the reaction product, TNB. This assay format can be used to screen the current MLSMR collection of compounds to find novel TGR inhibitors. Is the molecule effective to this assay?